ESPR 8-K 2026-01-12

Esperion Therapeutics, Inc. (ESPR) 8-K dated 2026-01-12 — accession 0001628280-26-001764. This URL is the filing, not the ESPR hub.

Esperion Therapeutics, Inc. (ESPR) is a drug manufacturers - specialty & generic company listed on NASDAQ.

Esperion Therapeutics, Inc. filed a 8-K on 2026-01-12. Accession 0001628280-26-001764.

Cached items: 2.02, 9.01. EDGAR remains the official archive; Lician keeps this accession as its own indexable page so Google can recrawl the form, not a ticker dump.

Latest reported ESPR revenue for 2025-12-31 was $403.1M. Net income was -$22.7M. Revenue was up 21.3% from 2024-12-31 to 2025-12-31. ESPR currently screens at market cap $816.9M.

Not investment advice. The ESPR SEC hub lists recent forms. The stock page is the research view.